Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances

Advances in Anatomic Pathology

Volumn 24, Issue 3, 2017, Pages 113-127

  Paner, Gladell P ^a   Montironi, Rodolfo ^a   Amin, Mahul B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

anatomic; bladder; cancer; diverticulum; histology; pT; staging; subsite; substaging; TNM

Indexed keywords

ADIPOSE TISSUE; BLADDER CANCER; BLADDER TRIGONE; BLADDER WALL; CANCER STAGING; CANCER SURVIVAL; COLONIC MUSCLE; CYSTECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; LYMPH NODE METASTASIS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROSTATE; REVIEW; SEMINAL VESICLE; SEX DIFFERENTIATION; STOMACH MUSCLE; TRANSURETHRAL RESECTION; ABNORMALITIES; BLADDER; DIAGNOSTIC IMAGING; DIVERTICULUM; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

CARCINOMA, TRANSITIONAL CELL; DIVERTICULUM; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 85017387235     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000152     Document Type: Review

References (160)

1. Amin MB, McKenney JK, Paner GP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: pathology. Eur Urol. 2013;63:16-35.
2. Cheng L, Montironi R, Davidson DD, et al. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009;22(suppl 2):S70-S95.
3. Hansel DE, Amin MB, Comperat E, et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol. 2013;63:321-332.
4. Babjuk M, Bohle A, Burger M, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447-461.
5. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196:1021-1029.
6. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778-792.
7. Milowsky MI, Rumble RB, Booth CM, et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology Clinical practice guideline endorsement. J Clin Oncol. 2016;34:1945-1952.
8. NCCN clinical practice guidelines in oncology (NCCN guidelines) bladder cancer. 2016. Available at: www.nccn. org/. Accessed February 12, 2017.
9. Bochner BH, Hansel DE, Efstathiou JA, et al. Urinary bladder. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual, 8th ed. Chicago, IL: Springer; 2017:757-765. Amin MB, Editor in Chief.
10. Mariappan P, Zachou A, Grigor KM, et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57:843-849.
11. Amin MB, Delahunt B, Bochner BH, et al. Protocol for the examination of specimens from patients with carcinoma of the urinary bladder. 2013. Available at: www.cap.org/. Accessed February 12, 2017.
12. Paner GP, Ro JY, Wojcik EM, et al. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol. 2007;31:1420-1429.
13. Cheng L, Neumann RM, Weaver AL, et al. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol. 1999;17:3182-3187.
14. Brimo F, Wu C, Zeizafoun N, et al. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol. 2013;44:95-102.
15. Dorschner WS, Stolzenburg J-U, Neuhaus J. The musculature of the trigonum vesicae. In: Dorschner WS, Stolzenburg J-U, Neuhaus J, eds. Advances in Anatomy, Embryology and Cell Biology. Structure and Function of the Bladder Neck. Berlin: Springer-Verlag; 2001:17-29.
16. Stephenson WT, Holmes FF, Noble MJ, et al. Analysis of bladder carcinoma by subsite. Cystoscopic location may have prognostic value. Cancer. 1990;66:1630-1635.
17. Minardi D, Milanese G, Parri G, et al. Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy Arch Ital Urol Androl. 2016;88:13-16.
18. Xiao GQ, Rashid H. Bladder neck urothelial carcinoma: a urinary bladder subsite carcinoma with distinct clinicopathology. Int J Surg Pathol. 2015;23:517-523.
19. Svatek RS, Clinton TN, Wilson CA, et al. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014;84: 1147-1151.
20. Wedel SA, Jones J, Tsaur I, et al. Association of intravesical tumor location with metastases to the pelvic lymph nodes in transitional cell cancer of the bladder. Am J Med Sci. 2010; 339:341-344.
21. Martin M, Bernardini S, Kleinclauss F, et al. Prognostic value of tumor location of urothelial tumors of the bladder, after total cystectomy. Prog Urol. 2002;12:1221-1227.
22. Vukomanovic I, Colovic V, Soldatovic I, et al. Prognostic significance of tumor location in high-grade non-muscleinvasive bladder cancer. Med Oncol. 2012;29:1916-1920.
23. Mulders PF, Meyden AP, Doesburg WH, et al. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group. Br J Urol. 1994;73:403-408.
24. Mungan MU, Canda AE, Tuzel E, et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol. 2005;48: 760-763.
25. Huang J, Fu J, Zhan H, et al. Analysis of the absence of the detrusor muscle in initial transurethral resected specimens and the presence of residual tumor tissue. Urol Int. 2012;89: 319-325.
26. Shoshany O, Mano R, Margel D, et al. Presence of detrusor muscle in bladder tumor specimens-predictors and effect on outcome as a measure of resection quality. Urol Oncol. 2014;32:40.e17-40.e22.
27. Farrow GM, Utz DC, Rife CC. Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res. 1976;36:2495-2501.
28. Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol. 1997;21: 1057-1068.
29. Lopez-Beltran A, Cheng L, Andersson L, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch. 2002;440:3-11.
30. Van Der Aa MN, Van Leenders GJ, Steyerberg EW, et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol. 2005;36:981-986.
31. Farrow GM, Utz DC. Observations on microinvasive transitional cell carcinoma of the urinary bladder. Clin Oncol. 1982;1:609-615.
32. McKenney JK, Gomez JA, Desai S, et al. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25:356-362.
33. Dixon JS, Gosling JA. Histology and fine structure of the muscularis mucosae of the human urinary bladder. J Anat. 1983;136:265-271.
34. Ro JY, Ayala AG, El-Naggar A. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol. 1987;11:668-673.
35. Keep JC, Piehl M, Miller A, et al. Invasive carcinomas of the urinary bladder. Evaluation of tunica muscularis mucosae involvement. Am J Clin Pathol. 1989;91:575-579.
36. Weaver MG, Abdul-Karim FW. The prevalence and character of the muscularis mucosae of the human urinary bladder. Histopathology. 1990;17:563-566.
37. Engel P, Anagnostaki L, Braendstrup O. The muscularis mucosae of the human urinary bladder. Implications for tumor staging on biopsies. Scand J Urol Nephrol. 1992;26: 249-252.
38. Vera-Sempere FJ, Jaen Martinez J, Vera Donoso CD, et al. Assessment of the tunica muscularis mucosae of the bladder wall: necropsy study. Actas Urol Esp. 1998;22:726-734.
39. Vakar-Lopez F, Shen SS, Zhang S, et al. Muscularis mucosae of the urinary bladder revisited with emphasis on its hyperplastic patterns: a study of a large series of cystectomy specimens. Ann Diagn Pathol. 2007;11:395-401.
40. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer. 1990;66: 543-548.
41. Fransen Van De Putte EE, Behrendt MA, Pigot GL, et al. Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder. Curr Opin Urol. 2015;25:427-435.
42. Hasui Y, Osada Y, Kitada S, et al. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology. 1994;43:782-786.
43. Angulo JC, Lopez JI, Grignon DJ, et al. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology. 1995;45:47-53.
44. Platz CE, Cohen MB, Jones MP, et al. Is microstaging of early invasive cancer of the urinary bladder possible or useful Mod Pathol. 1996;9:1035-1039.
45. Holmang S, Hedelin H, Anderstrom C, et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol. 1997;157:800-803.
46. Smits G, Schaafsma E, Kiemeney L, et al. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology. 1998;52:1009-1013.
47. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol. 1998;159:91-94.
48. Kondylis FI, Demirci S, Ladaga L, et al. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol. 2000;163:1120-1123.
49. Shariat SF, Weizer AZ, Green A, et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000;56:735-740.
50. Bernardini S, Billerey C, Martin M, et al. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol. 2001;165: 42-46.
51. Sozen S, Akbal C, Sokmensuer C, et al. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses (pT1 subcategory). Urol Int. 2002;69:200-206.
52. Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005;48:231-238.
53. Andius P, Johansson SL, Holmang S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology. 2007;70:758-762.
54. Mhawech-Fauceglia P, Fischer G, Alvarez V Jr, et al. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int. 2007;100:1182-1187.
55. Orsola A, Cecchini L, Raventos CX, et al. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guerin therapy and the decision for a repeat TUR. BJU Int. 2010;105:202-207.
56. Faivre d'Arcier B, Celhay O, Safsaf A, et al. T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU). Prog Urol. 2010;20: 440-449.
57. Bertz S, Denzinger S, Otto W, et al. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology. 2011;59: 722-732.
58. Lee JY, Joo HJ, Cho DS, et al. Prognostic significance of substaging according to the depth of lamina propria invasion in primary T1 transitional cell carcinoma of the bladder. Korean J Urol. 2012;53:317-323.
59. Van Rhijn BW, Van Der Kwast TH, Alkhateeb SS, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol. 2012;61:378-384.
60. Chang WC, Chang YH, Pan CC. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection. Am J Surg Pathol. 2012;36: 454-461.
61. Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol. 2012;62:118-125.
62. Roupre t M, Seisen T, Comperat E, et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol. 2013;189:2069-2076.
63. Nguyen-Huu Y, Delorme G, Lillaz J, et al. Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma. Prog Urol. 2012;22:284-290.
64. Olsson H, Hultman P, Rosell J, et al. Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours. Scand J Urol. 2013;47: 188-195.
65. Soukup V, Duskova J, Pesl M, et al. The prognostic value of T1 bladder cancer substaging: a single institution retrospective study. Urol Int. 2014;92:150-156.
66. De Marco V, Cerruto MA, D'Elia C, et al. Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder. Mol Clin Oncol. 2014;2:575-580.
67. Orsola A, Werner L, De Torres I, et al. Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer. 2015;112:468-474.
68. Patschan O, Sjodahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol. 2015;68:824-832.
69. Patriarca C, Hurle R, Moschini M, et al. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagn Pathol. 2016;11:6.
70. Hu Z, Mudaliar K, Quek ML, et al. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence. Ann Diagn Pathol. 2014;18:49-52.
71. Nishiyama N, Kitamura H, Maeda T, et al. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system. Jpn J Clin Oncol. 2013;43: 1124-1131.
72. Bol MG, Baak JP, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol. 2003;169:1291-1294.
73. Van Rhijn BW, Van Der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int. 2010;106:206-211.
74. Giunchi F, Panzacchi R, Capizzi E, et al. Role of interobserver variability and quantification of muscularis propria in the pathological staging of bladder cancer. Clin Genitourin Cancer. 2016;14:e307-e312.
75. Van Der Meijden A, Sylvester R, Collette L, et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol. 2000;164:1533-1537.
76. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int. 2000;85:48-53.
77. Compérat E, Egevad L, Lopez-Beltran A, et al. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology. 2013;63:756-766.
78. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010;57:300-309.
79. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007;51:137-149.
80. Lopez-Beltran A, Algaba F, Berney DM, et al. Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP). Histopathology. 2011;58:579-585.
81. Moch H, Humphrey PA, Ulbright TM, et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th ed. Geneva: WHO Press; 2016.
82. Comperat E, Varinot J. Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification. Histopathology. 2016;69:717-726.
83. Hurle R, Lazzeri M, Colombo P, et al. "En Bloc" resection of nonmuscle invasive bladder cancer: a prospective singlecenter study. Urology. 2016;90:126-130.
84. Herrmann TR, Wolters M, Kramer MW. Transurethral en bloc resection of nonmuscle invasive bladder cancer: trend or hype. Curr Opin Urol. 2017;27:182-190.
85. Kramer MW, Rassweiler JJ, Klein J, et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol. 2015;33:1937-1943.
86. Naselli A, Puppo P. En bloc transurethral resection of bladder tumors: a new standard J Endourol. 2017. [Epub ahead of print].
87. Council L, Hameed O. Differential expression of immunohistochemical markers in bladder smooth muscle and myofibroblasts, and the potential utility of desmin, smoothelin, and vimentin in staging of bladder carcinoma. Mod Pathol. 2009;22:639-650.
88. Paner GP, Shen SS, Lapetino S, et al. Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol. 2009;33:91-98.
89. Paner GP, Brown JG, Lapetino S, et al. Diagnostic use of antibody to smoothelin in the recognition of muscularis propria in transurethral resection of urinary bladder tumor (TURBT) specimens. Am J Surg Pathol. 2010;34:792-799.
90. Bovio IM, Al-Quran SZ, Rosser CJ, et al. Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder carcinoma. Histopathology. 2010;56:951-956.
91. Miyamoto H, Sharma RB, Illei PB, et al. Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma. Am J Surg Pathol. 2010;34:418-422.
92. Chakravarthy R, Ahmed K, Abbasi S, et al. In response-a modified staining protocol for smoothelin immunostaining. Virchows Arch. 2011;459:119-120.
93. Amin MB, Trpkov K, Lopez-Beltran A, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38:e20-e34.
94. Van Der Loop FT, Schaart G, Timmer ED, et al. Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J Cell Biol. 1996;134:401-411.
95. Maake C, Landman M, Wang X, et al. Expression of smoothelin in the normal and the overactive human bladder. J Urol. 2006;175:1152-1157.
96. Lindh C, Nilsson R, Lindstrom ML, et al. Detection of smoothelin expression in the urinary bladder is strongly dependent on pretreatment conditions: a critical analysis with possible consequences for cancer staging. Virchows Arch. 2011;458:665-670.
97. Dorschner WS, Stolzenburg J-U, Neuhaus J. Musculus detrusor vesicae. In: Dorschner WS, Stolzenburg J-U, Neuhaus J, eds. Advances in Anatomy, Embryology and Cell Biology Structure and Function of the Bladder Neck. Berlin: Springer-Verlag; 2001:7-14.
98. Ananthanarayanan V, Pan Y, Tretiakova M, et al. Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologists. Am J Surg Pathol. 2014;38:167-175.
99. Philip AT, Amin MB, Tamboli P, et al. Intravesical adipose tissue: a quantitative study of its presence and location with implications for therapy and prognosis. Am J Surg Pathol. 2000;24:1286-1290.
100. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102:1242-1246.
101. Mariappan P, Finney SM, Head E, et al. Good quality whitelight transurethral resection of bladder tumours (GQWLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 2012;109:1666-1673.
102. Roupret M, Yates DR, Varinot J, et al. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. Can J Urol. 2012;19: 6459-6464.
103. Tilki D, Reich O, Karakiewicz PI, et al. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol. 2010;58:112-117.
104. Sonpavde G, Khan MM, Svatek RS, et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2011;108:687-692.
105. Ghoneim MA, Abdel-Latif M, El-Mekresh M, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 2008;180:121-127.
106. Gakis G, Schilling D, Renninger M, et al. Comparison of the new American Joint Committee on Cancer substratification in node-negative pT2 urothelial carcinoma of the bladder: analysis of patient outcomes in a contemporary series. BJU Int. 2011;107:919-923.
107. Boudreaux KJ Jr, Clark PE, Lowrance WT, et al. Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009;181:540-545.
108. Zarei S, Frank I, Boorjian SA, et al. Prognostic significance of measured depth of invasion of urothelial carcinoma of the bladder compared to the 2010 American Joint Committee on Cancer pT2 and pT3 classifications. J Urol. 2012;188: 1706-1711.
109. Yu RJ, Stein JP, Cai J, et al. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol. 2006;176:493-498.
110. Cheng L, Neumann RM, Scherer BG, et al. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer. 1999;85:2638-2647.
111. Tokgoz H, Turkolmez K, Resorlu B, et al. Pathological staging of muscle invasive bladder cancer. Is substaging of pT2 tumors really necessary Int Braz J Urol. 2007;33: 777-783.
112. Girgin C, Sezer A, Delibas M, et al. Impact of the level of muscle invasion in organ-confined bladder cancer. Urol Int. 2007;78:145-149.
113. Herranz Amo F, Verdu Tartajo F, Diez Cordero JM, et al. Differences in survival of patients with bladder cancer depending on depth of muscle infiltration. Actas Urol Esp. 2001;25:110-114.
114. Scosyrev E, Yao J, Messing E. Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice. Urology. 2010;76:908-914.
115. Neuzillet Y, Lebret T, Molinie V, et al. Perivesical fat invasion in bladder cancer: implications for prognosis comparing pT2b, pT3a and pT3b stages and consequences for adjuvant chemotherapy indications. BJU Int. 2012;110: 1736-1741.
116. Bastian PJ, Hutterer GC, Shariat SF, et al. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int. 2008;101:450-454.
117. Sonpavde G, Khan MM, Svatek RS, et al. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011;185:1216-1221.
118. Tilki D, Svatek RS, Karakiewicz PI, et al. pT3 substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol. 2010;184:470-474.
119. Quek ML, Stein JP, Clark PE, et al. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004;171:640-645.
120. Boudreaux KJ Jr, Chang SS, Lowrance WT, et al. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009;115:770-775.
121. Dincel C, Kara C, Balci U, et al. Comparison of microscopic (pT3a) and gross extravesical extension (pT3b) in pathological staging of bladder cancer: analysis of patient outcomes. Int Urol Nephrol. 2013;45:387-393.
122. Tretter EM, Ebel JJ, Pohar KS, et al. Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer Hum Pathol. 2016;61:190-198.
123. Walker NF, Gan C, Olsburgh J, et al. Diagnosis and management of intradiverticular bladder tumours. Nat Rev Urol. 2014;11:383-390.
124. Hansel DE, Paner GP, Nese N, et al. Limited smoothelin expression within the muscularis mucosae: validation in bladder diverticula. Hum Pathol. 2011;42:1770-1776.
125. Golijanin D, Yossepowitch O, Beck SD, et al. Carcinoma in a bladder diverticulum: presentation and treatment outcome. J Urol. 2003;170:1761-1764.
126. Idrees MT, Alexander RE, Kum JB, et al. The spectrum of histopathologic findings in vesical diverticulum: implications for pathogenesis and staging. Hum Pathol. 2013;44:1223-1232.
127. Tamas EF, Stephenson AJ, Campbell SC, et al. Histopathologic features and clinical outcomes in 71 cases of bladder diverticula. Arch Pathol Lab Med. 2009;133:791-796.
128. Hu B, Satkunasivam R, Schuckman A, et al. Urothelial carcinoma in bladder diverticula: outcomes after radical cystectomy. World J Urol. 2015;33:1397-1402.
129. Kong MX, Zhao X, Kheterpal E, et al. Histopathologic and clinical features of vesical diverticula. Urology. 2013;82:142-147.
130. Zhong H, George S, Kauffman E, et al. Clinicopathologic characterization of intradiverticular carcinoma of urinary bladder-a study of 22 cases from a single cancer center. Diagn Pathol. 2014;9:222-228.
131. Dhillon J, Liang Y, Kamat AM, et al. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015;46: 1808-1814.
132. Molina JR, Quevedo JF, Furth AF, et al. Predictors of survival from urachal cancer: aMayo Clinic study of 49 cases. Cancer. 2007;110:2434-2440.
133. Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107:712-720.
134. Pinthus JH, Haddad R, Trachtenberg J, et al. Population based survival data on urachal tumors. J Urol. 2006;175: 2042-2047.
135. Sheldon CA, Clayman RV, Gonzalez R, et al. Malignant urachal lesions. J Urol. 1984;131:1-8.
136. Paner GP, Lopez-Beltran A, Sirohi D, et al. Updates in the pathologic diagnosis and classification of epithelial neoplasms of urachal origin. Adv Anat Pathol. 2016;23:71-83.
137. Knoedler JJ, Boorjian SA, Tollefson MK, et al. Urothelial carcinoma involving the prostate: the association of revised tumour stage and coexistent bladder cancer with survival after radical cystectomy. BJU Int. 2014;114:832-836.
138. Barocas DA, Patel SG, Chang SS, et al. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009;104:1091-1097.
139. Njinou Ngninkeu B, Lorge F, Moulin P, et al. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol. 2003;169:149-152.
140. Esrig D, Freeman JA, Elmajian DA, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol. 1996;156:1071-1076.
141. Pagano F, Bassi P, Ferrante GL, et al. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer A necessary distinction for contiguous or noncontiguous involvement. J Urol. 1996;155:244-247.
142. Ayyathurai R, Gomez P, Luongo T, et al. Prostatic involvement by urothelial carcinoma of the bladder: clinicopathological features and outcome after radical cystectomy. BJU Int. 2007;100:1021-1025.
143. Shen SS, Lerner SP,Muezzinoglu B, et al. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37:726-734.
144. Montironi R, Cheng L, Mazzucchelli R, et al. Critical evaluation of the prostate from cystoprostatectomies for bladder cancer: insights from a complete sampling with the whole mount technique. Eur Urol. 2009;55:1305-1309.
145. Donat SM, Genega EM, Herr HW, et al. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol. 2001;165:1117-1120.
146. Vallo S, Gilfrich C, Burger M, et al. Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. Urol Oncol. 2016;34:432.e1-432.e8.
147. Patel AR, Cohn JA, Abd El Latif A, et al. Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma. J Urol. 2013;189:53-58.
148. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010: 497-510.
149. Liberman D, Alasker A, Sun M, et al. Radical cystectomy for patients with pT4 urothelial carcinoma in a large populationbased study. BJU Int. 2011;107:905-911.
150. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001;165: 1111-1116.
151. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675.
152. May M, Brookman-May S, Burger M, et al. Concomitant seminal vesicle invasion in pT4a urothelial carcinoma of the bladder with contiguous prostatic infiltration is an adverse prognosticator for cancer-specific survival after radical cystectomy. Ann Surg Oncol. 2014;21:4034-4040.
153. You D, Kim SC, Jeong IG, et al. Urothelial carcinoma of the bladder with seminal vesicle invasion: prognostic significance. BJU Int. 2010;106:1657-1661.
154. Daneshmand S, Stein JP, Lesser T, et al. Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. J Urol. 2004;172:81-84.
155. Aziz A, Shariat SF, Roghmann F, et al. Prediction of cancerspecific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. BJU Int. 2016;117:272-279.
156. May M, Bastian PJ, Brookman-May S, et al. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urol Oncol. 2013;31:1141-1147.
157. Tilki D, Reich O, Svatek RS, et al. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010;183:1757-1763.
158. Marks P, Soave A, Shariat SF, et al. Female with bladder cancer: what and why is there a difference Transl Androl Urol. 2016;5:668-682.
159. Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69:300-310.
160. Kluth LA, Rieken M, Xylinas E, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol. 2014;66:913-919.